Pharmacogenomics

Detection of 6 mutations associated with dihydropyrimidine dehydrogenase deficiency.

Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+/HER2- primary breast cancer.

Kit based on the screening of HLA-B * 57:01 allele using real-time PCR with Taqman ® probes

The most comprehensive tumor test to determine Homologous Recombination Deficiency (HDR) Status by studying the BRCA genes in patients with ovarian cancer.

La prueba más completa para determinar el estado de deficiencia de la recombinación homóloga (HDR) estudiando los genes BRCA y 13 más adicionales, en pacientes con cáncer de ovario.